BIOCON LTD BIOS
COM · Common Stock · CUSIP Y0905C102
2
institutional holders
+0 vs Q1 2024
1.3m
shares reported held*
$5.7mreported value*
0 new
0 added
1 reduced
0 sold out
net sold ≈ $17.1k (-4.1k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $4.21.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2023 | 1 |
| Q2 2023 | 1 |
| Q3 2023 | 1 |
| Q4 2023 | 1 |
| Q1 2024 | 2 |
| Q2 2024 | 2 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q2 2023 | 0 | 1 |
| Q3 2023 | 0 | 1 |
| Q4 2023 | 0 | 1 |
| Q1 2024 | 2 | 0 |
| Q2 2024 | 0 | 1 |
Biggest buyers
| None |
Biggest sellers
| Boston Common Asset Management, LLC | Reduced | -4.1k |
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| Stanley-Laman Group, Ltd. 0.48% of their portfolio | 800.0k $3.4m | Unchanged |
| Boston Common Asset Management, LLC 0.06% of their portfolio | 549.5k $2.3m | Reduced -4.1k |